Clinical Trial

A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
Randomized, double-blind, placebo-controlled study of HRS9531 in PCOS subjects
Trial Details
NCT Number NCT06595797
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Obese Subjects With Polycystic Ovary Syndrome (PCOS)
Enrollment 144 participants
Start Date 2024-09
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2024-09-19